These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36894038)

  • 21. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
    Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
    N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
    Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
    BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA).
    Cheung AK; Hurley B; Kerrigan R; Shu L; Chin DN; Shen Y; O'Brien G; Sung MJ; Hou Y; Axford J; Cody E; Sun R; Fazal A; Fridrich C; Sanchez CC; Tomlinson RC; Jain M; Deng L; Hoffmaster K; Song C; Van Hoosear M; Shin Y; Servais R; Towler C; Hild M; Curtis D; Dietrich WF; Hamann LG; Briner K; Chen KS; Kobayashi D; Sivasankaran R; Dales NA
    J Med Chem; 2018 Dec; 61(24):11021-11036. PubMed ID: 30407821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.
    Ottesen EW; Singh NN; Luo D; Kaas B; Gillette BJ; Seo J; Jorgensen HJ; Singh RN
    Nucleic Acids Res; 2023 Jul; 51(12):5948-5980. PubMed ID: 37026480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
    Naryshkin NA; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling KK; Karp GM; Qi H; Woll MG; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; Lee CS; Zhang X; Moon YC; Trifillis P; Welch EM; Colacino JM; Babiak J; Almstead NG; Peltz SW; Eng LA; Chen KS; Mull JL; Lynes MS; Rubin LL; Fontoura P; Santarelli L; Haehnke D; McCarthy KD; Schmucki R; Ebeling M; Sivaramakrishnan M; Ko CP; Paushkin SV; Ratni H; Gerlach I; Ghosh A; Metzger F
    Science; 2014 Aug; 345(6197):688-93. PubMed ID: 25104390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes.
    Singh NN; Seo J; Rahn SJ; Singh RN
    PLoS One; 2012; 7(11):e49595. PubMed ID: 23185376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy.
    Pinard E; Green L; Reutlinger M; Weetall M; Naryshkin NA; Baird J; Chen KS; Paushkin SV; Metzger F; Ratni H
    J Med Chem; 2017 May; 60(10):4444-4457. PubMed ID: 28441483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
    Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
    Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1.
    Hofmann Y; Wirth B
    Hum Mol Genet; 2002 Aug; 11(17):2037-49. PubMed ID: 12165565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving concepts on human SMN pre-mRNA splicing.
    Singh RN
    RNA Biol; 2007; 4(1):7-10. PubMed ID: 17592254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).
    Hofmann Y; Lorson CL; Stamm S; Androphy EJ; Wirth B
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9618-23. PubMed ID: 10931943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
    Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
    Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risdiplam in Type 1 Spinal Muscular Atrophy.
    Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
    N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
    Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy.
    Hastings ML; Berniac J; Liu YH; Abato P; Jodelka FM; Barthel L; Kumar S; Dudley C; Nelson M; Larson K; Edmonds J; Bowser T; Draper M; Higgins P; Krainer AR
    Sci Transl Med; 2009 Nov; 1(5):5ra12. PubMed ID: 20161659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
    Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients.
    Andreassi C; Jarecki J; Zhou J; Coovert DD; Monani UR; Chen X; Whitney M; Pollok B; Zhang M; Androphy E; Burghes AH
    Hum Mol Genet; 2001 Nov; 10(24):2841-9. PubMed ID: 11734549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
    Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A; Jiang X; He L; Ahmad S; Gangwani L
    Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
    Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
    Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.